The use of nucleoside and nucleotide analogs to inhibit the viral RNA polymerase, thereby preventing propagation of the virus, is a well-documented and historically successful approach to treatment of various viral diseases, including HIV/AIDS, herpesvirus, hepatitis B and hepatitis C infections.


Uniquely active against RNA viruses.

We have produced a large library of nucleoside and nucleotide analogs prodrugs that specifically target viral RNA polymerases. Based on extensive knowledge and years of experience discovering and developing antivirals, our team of scientists has designed product candidates that include specific chemical modifications intended to enhance antiviral activity and maximize selectivity.

Unique prodrugs of nucleotide analogs are intrinsic to Atea’s innovative platform for developing orally administered, direct-acting antiviral therapies.

A graphic illustration of Atea’s different generations of phosphoramidates.

Atea's Oral Antiviral Platform has Potential to Transform Treatment of Severe Viral Diseases

A platform of proprietary purine nucleos(t)ide prodrugs designed specifically to target viral RNA polymerase.

Nucleos(t)ide drugs are well suited for mono- and combination treatment regimens.

Treatment of most RNA viral diseases require combination regimens to prevent drug resistance

Coronaviridae Icon

SARS-CoV-2 and Future Coronaviruses

Flaviviridae Icon


Atea’s Advanced Antiviral Pipeline

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with serious viral  infections. Currently, Atea is focused on the development of orally-available antiviral agents for serious viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C virus (HCV).

Pipeline & Programs